PDT Partners LLC Buys New Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

PDT Partners LLC purchased a new position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 252,959 shares of the biopharmaceutical company's stock, valued at approximately $2,702,000. PDT Partners LLC owned 0.08% of Amicus Therapeutics at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in FOLD. Vinva Investment Management Ltd bought a new stake in shares of Amicus Therapeutics in the 3rd quarter valued at about $143,000. FORA Capital LLC purchased a new position in shares of Amicus Therapeutics in the third quarter worth about $313,000. BNP Paribas Financial Markets raised its stake in Amicus Therapeutics by 66.1% during the third quarter. BNP Paribas Financial Markets now owns 565,976 shares of the biopharmaceutical company's stock worth $6,045,000 after purchasing an additional 225,222 shares during the period. Algert Global LLC raised its stake in Amicus Therapeutics by 192.6% during the third quarter. Algert Global LLC now owns 259,160 shares of the biopharmaceutical company's stock worth $2,768,000 after purchasing an additional 170,575 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Amicus Therapeutics by 10.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,667,271 shares of the biopharmaceutical company's stock valued at $28,486,000 after acquiring an additional 242,672 shares during the period.

Analyst Upgrades and Downgrades

FOLD has been the subject of a number of research reports. Needham & Company LLC restated a "hold" rating on shares of Amicus Therapeutics in a report on Thursday, November 7th. JPMorgan Chase & Co. upped their price target on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the company an "overweight" rating in a research report on Tuesday, November 12th. StockNews.com upgraded shares of Amicus Therapeutics from a "hold" rating to a "buy" rating in a research report on Saturday, November 16th. Jefferies Financial Group assumed coverage on shares of Amicus Therapeutics in a research report on Friday, September 6th. They set a "buy" rating and a $18.00 price objective for the company. Finally, Bank of America upped their price target on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a "buy" rating in a research note on Thursday, October 17th. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $17.63.

Insider Transactions at Amicus Therapeutics

In other news, CEO Bradley L. Campbell sold 7,500 shares of Amicus Therapeutics stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $11.71, for a total transaction of $87,825.00. Following the transaction, the chief executive officer now owns 886,654 shares in the company, valued at $10,382,718.34. The trade was a 0.84 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold a total of 30,401 shares of company stock worth $352,038 over the last three months. 2.20% of the stock is currently owned by insiders.

Amicus Therapeutics Stock Up 0.2 %

Shares of Amicus Therapeutics stock traded up $0.02 during trading on Friday, hitting $9.98. 818,677 shares of the stock traded hands, compared to its average volume of 2,427,854. The stock has a market cap of $2.98 billion, a P/E ratio of -29.35 and a beta of 0.68. The company has a debt-to-equity ratio of 2.18, a quick ratio of 2.42 and a current ratio of 3.15. Amicus Therapeutics, Inc. has a twelve month low of $9.02 and a twelve month high of $14.57. The company has a fifty day moving average price of $10.70 and a two-hundred day moving average price of $10.60.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.